Metastatic Prostate Cancer - Epidemiology Forecast - 2034
Description
Key Highlights
In 2023, there were around 8,241,400 prevalent cases of prostate cancer in the 7MM, which is expected to rise by 2034, and the United States had the highest number of prevalent cases of prostate cancer among the 7MM.
Germany had the highest number of diagnosed prevalent cases of prostate cancer in the EU4 countries, followed by France, whereas Spain had the lowest number of cases.
Among the age specific data, 65–74 years of age group was most prevalent, accounting for ~40% of cases in the United States, followed by 55–64, and the least number of cases were observed with people above 84 years.
Around 45% of the patients had mCSPC/mHSPC, and around 55% had mCRPC.
Studies show a continued increase in the incidence of distant-stage prostate cancer in the United States. The percentage of distant-stage prostate cancer increased from 4% in 2003 to 8% in 2017.
DelveInsight’s “Metastatic Prostate Cancer – Epidemiology Forecast – 2034” report delivers an in-depth understanding of metastatic prostate cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metastatic Prostate Cancer Disease Understanding
Metastatic Prostate Cancer Overview
Prostate cancer is a type of malignancy in the prostate gland, a part of the male reproductive system. Metastatic prostate cancer spreads from the prostate to other parts of the body, sometimes called advanced prostate cancer. It most commonly spreads to lymph nodes in other parts of the body or to the bones and can also spread to other organs, such as the lungs. Metastatic hormone-sensitive prostate cancer (mHSPC) is when cancer has spread past the prostate into the body, but it can be treated with hormone therapy. In the case of metastatic castration-resistant prostate cancer (mCRPC), the cancer stops responding to hormone treatment.
Metastatic Prostate Cancer Diagnosis
Diagnosis is primarily based on prostate-specific antigen (PSA) testing, which is elevated in those with prostate cancer or other conditions affecting the prostate. Screening can also involve a digital rectal exam to feel for prominent prostate tumors, a prostate ultrasound, and a prostate MRI. A definitive diagnosis requires a transrectal ultrasound-guided (TRUS) prostate tissue biopsy. When the cancer is limited to the prostate, it is considered localized and potentially curable. Active surveillance, surgery, or radiation therapy are the three major treatment options for localized or locally advanced prostate cancer.
Further details related to diagnosis will be provided in the report…
Metastatic Prostate Cancer Epidemiology
The metastatic prostate cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of prostate cancer, total diagnosed cases of prostate cancer, age-specific cases of prostate cancer, total diagnosed cases of prostate cancer by clinical stages, total metastatic cases of prostate cancer, total treated cases of mCRPC, and total treated cases of mCSPC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2023 to 2034.
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., 2024-2034.
The United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,000 reported cases, in 2023.
The highest number of cases were found in people aged between 65-74 years, accounting for approximately 1,299,700 cases in 2023.
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in the locally advanced stage (Stage I–III) followed by biochemical recurrence/progressive and metastatic stages.
Among the EU4, Germany accounted for the highest number of prevalent metastatic prostate cancer cases, followed by France, whereas Spain occupied the bottom of the ladder.
The total number of diagnosed prevalent cases of prostate cancer in Japan was ~282,000 in 2023 and is expected to increase during the forecast period, i.e. 2024–2034.
KOL Views
To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the metastatic prostate cancer evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers and organizations such as MD Anderson Cancer Center, Prostate Cancer Foundation (PCF), Prostate Cancer UK, Institute for Prostate Cancer Research (IPCR), etc., were contacted. Their opinion helps understand and validate epidemiological trends of metastatic prostate cancer.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of metastatic prostate cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of the metastatic prostate cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Metastatic Prostate Cancer Report Insights
Patient Population
Patient population by stage and age
Country-wise Epidemiology Distribution
Metastatic Prostate Cancer Report Key Strengths
11 Years Forecast
The 7MM Coverage
Metastatic Prostate Cancer Epidemiology Segmentation
Metastatic Prostate Cancer Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
Key Questions
Epidemiology Insights:
What are the disease risks and burdens of metastatic prostate cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic prostate cancer?
What is the historical and forecasted metastatic prostate cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Which age group is the largest contributor in patients affected with metastatic prostate cancer?
Which clinical stage has the highest patient number in prostate cancer?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
In 2023, there were around 8,241,400 prevalent cases of prostate cancer in the 7MM, which is expected to rise by 2034, and the United States had the highest number of prevalent cases of prostate cancer among the 7MM.
Germany had the highest number of diagnosed prevalent cases of prostate cancer in the EU4 countries, followed by France, whereas Spain had the lowest number of cases.
Among the age specific data, 65–74 years of age group was most prevalent, accounting for ~40% of cases in the United States, followed by 55–64, and the least number of cases were observed with people above 84 years.
Around 45% of the patients had mCSPC/mHSPC, and around 55% had mCRPC.
Studies show a continued increase in the incidence of distant-stage prostate cancer in the United States. The percentage of distant-stage prostate cancer increased from 4% in 2003 to 8% in 2017.
DelveInsight’s “Metastatic Prostate Cancer – Epidemiology Forecast – 2034” report delivers an in-depth understanding of metastatic prostate cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Metastatic Prostate Cancer Disease Understanding
Metastatic Prostate Cancer Overview
Prostate cancer is a type of malignancy in the prostate gland, a part of the male reproductive system. Metastatic prostate cancer spreads from the prostate to other parts of the body, sometimes called advanced prostate cancer. It most commonly spreads to lymph nodes in other parts of the body or to the bones and can also spread to other organs, such as the lungs. Metastatic hormone-sensitive prostate cancer (mHSPC) is when cancer has spread past the prostate into the body, but it can be treated with hormone therapy. In the case of metastatic castration-resistant prostate cancer (mCRPC), the cancer stops responding to hormone treatment.
Metastatic Prostate Cancer Diagnosis
Diagnosis is primarily based on prostate-specific antigen (PSA) testing, which is elevated in those with prostate cancer or other conditions affecting the prostate. Screening can also involve a digital rectal exam to feel for prominent prostate tumors, a prostate ultrasound, and a prostate MRI. A definitive diagnosis requires a transrectal ultrasound-guided (TRUS) prostate tissue biopsy. When the cancer is limited to the prostate, it is considered localized and potentially curable. Active surveillance, surgery, or radiation therapy are the three major treatment options for localized or locally advanced prostate cancer.
Further details related to diagnosis will be provided in the report…
Metastatic Prostate Cancer Epidemiology
The metastatic prostate cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of prostate cancer, total diagnosed cases of prostate cancer, age-specific cases of prostate cancer, total diagnosed cases of prostate cancer by clinical stages, total metastatic cases of prostate cancer, total treated cases of mCRPC, and total treated cases of mCSPC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2023 to 2034.
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., 2024-2034.
The United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,000 reported cases, in 2023.
The highest number of cases were found in people aged between 65-74 years, accounting for approximately 1,299,700 cases in 2023.
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in the locally advanced stage (Stage I–III) followed by biochemical recurrence/progressive and metastatic stages.
Among the EU4, Germany accounted for the highest number of prevalent metastatic prostate cancer cases, followed by France, whereas Spain occupied the bottom of the ladder.
The total number of diagnosed prevalent cases of prostate cancer in Japan was ~282,000 in 2023 and is expected to increase during the forecast period, i.e. 2024–2034.
KOL Views
To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the metastatic prostate cancer evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.
DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers and organizations such as MD Anderson Cancer Center, Prostate Cancer Foundation (PCF), Prostate Cancer UK, Institute for Prostate Cancer Research (IPCR), etc., were contacted. Their opinion helps understand and validate epidemiological trends of metastatic prostate cancer.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of metastatic prostate cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of the metastatic prostate cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Metastatic Prostate Cancer Report Insights
Patient Population
Patient population by stage and age
Country-wise Epidemiology Distribution
Metastatic Prostate Cancer Report Key Strengths
11 Years Forecast
The 7MM Coverage
Metastatic Prostate Cancer Epidemiology Segmentation
Metastatic Prostate Cancer Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
Key Questions
Epidemiology Insights:
What are the disease risks and burdens of metastatic prostate cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic prostate cancer?
What is the historical and forecasted metastatic prostate cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Which age group is the largest contributor in patients affected with metastatic prostate cancer?
Which clinical stage has the highest patient number in prostate cancer?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
263 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of Prostate Cancer
- 4. Epidemiology Forecast Methodology
- 5. Disease Background and Overview
- 5.1. Signs and Symptoms of Prostate Cancer
- 5.2. Early Symptoms of Prostate Cancer
- 5.3. Advanced Prostate Cancer Symptoms
- 5.3.1. Recurrent Prostate Cancer Symptoms
- 5.4. Risk Factors and Causes of Prostate Cancer
- 5.5. Pathophysiology of Prostate Cancer
- 5.6. Prostate Neoplasia
- 5.7. Genetics of Prostate Cancer
- 5.7.1. Somatic Copy Number Alteration
- 5.7.2. Structural Rearrangements
- 5.7.3. Point Mutations
- 5.7.4. Single nucleotide polymorphisms (SNPs)
- 5.8. Diagnosis of Prostate Cancer
- 5.8.1.1. Screening Tests for Prostate Cancer
- 5.8.1.2. Tests to Diagnose Prostate Cancer
- 5.8.1.3. Stages and Grades of Prostate Cancer
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.2.1. Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- 6.2.2. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 6.3. Total Metastatic Cases of Prostate Cancer in the 7MM
- 6.4. The United States
- 6.4.1. Total Prevalent Cases of Prostate Cancer in the United States
- 6.4.2. Total Diagnosed Prevalent Cases of Prostate Cancer in the United States
- 6.4.3. Age-specific Cases of Prostate Cancer in the United States
- 6.4.4. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
- 6.4.5. Total Metastatic Cases of Prostate Cancer in the United States
- 6.4.6. Total Treated Cases of mCRPC in the United States
- 6.4.7. Total Treated Cases of mCSPC/mHSPC in the United States
- 6.5. EU4 and the UK
- 6.5.1. Total Prevalent Cases of Prostate Cancer in EU4 and the UK
- 6.5.2. Total Diagnosed Prevalent Cases of Prostate Cancer in EU4 and the UK
- 6.5.3. Age-specific Cases of Prostate Cancer in EU4 and the UK
- 6.5.4. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in EU4 and the UK
- 6.5.5. Total Metastatic Cases of Prostate Cancer in EU4 and the UK
- 6.5.6. Total Treated Cases of mCRPC in EU4 and the UK
- 6.5.7. Total Treated Cases of mCSPC/mHSPC in EU4 and the UK
- 6.6. Japan
- 6.6.1. Total Prevalent Cases of Prostate Cancer in Japan
- 6.6.2. Total Diagnosed Cases of Prostate Cancer in Japan
- 6.6.3. Age-specific Cases of Prostate Cancer in Japan
- 6.6.4. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in Japan
- 6.6.5. Total Metastatic Cases of Prostate Cancer in Japan
- 6.6.6. Total Treated Cases of mCRPC in Japan
- 6.6.7. Total Treated Cases of mCSPC/mHSPC in Japan
- 7. Appendix
- 7.1.1. Bibliography
- 7.1.2. Report Methodology
- 8. DelveInsight Capabilities
- 9. Disclaimer
- 10. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
